Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients—exploratory results from TITAN-RCC
Our findings revealed that neither the presence of autoantibodies at baseline nor the new occurrence of the majority of investigated autoantibodies during ICI therapy did predict irAE development in RCC patients. However, the appearance of novel autoantibodies and irAEs during therapy may represent markers for treatment efficacy.
Authors
- Rebekka Wehner
- Marc‐Oliver Grimm (ORCID: https://orcid.org/0000-0003-3084-8654)
- R Rothe (ORCID: https://orcid.org/0000-0002-0615-1112)
- Nadja Röber
- Ulrike Schumacher (ORCID: https://orcid.org/0000-0002-4546-8497)
- Philippe Barthélémy (ORCID: https://orcid.org/0000-0003-3917-0579)
- Katharina Leucht (ORCID: https://orcid.org/0000-0002-7450-6958)
- Emilio Esteban (ORCID: https://orcid.org/0000-0002-2980-5254)
- Manuela Schmidinger (ORCID: https://orcid.org/0000-0002-2567-2749)
- Marc Schmitz (ORCID: https://orcid.org/0000-0003-3417-6736)
- Karsten Conrad (ORCID: https://orcid.org/0000-0001-7581-6117)
- A Fritzsch
Institutions
- Institut de Cancérologie Strasbourg (FR)
- Hospital Universitario Central de Asturias (ES)
- University Hospital Carl Gustav Carus (DE)
- Université de Strasbourg (FR)
- Medical University of Vienna (AT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105575
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00